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Background: Little is known about the characteristics, evaluation and treatment of women with gout.
Objective: To examine the epidemiological differences and differences in treatment between men and
women in a large patient population.
Methods: The data from approximately 1.4 million people who were members of seven managed care
plans in the USA for at least 1 year between 1 January 1999 and 31 December 2003 were examined.
Adult members who had pharmacy benefits and at least two ambulatory claims specifying a diagnosis of
gout were identified. In addition, men and women who were new users of urate-lowering drugs (ULDs)
were identified to assess adherence with recommended surveillance of serum urate levels within 6 months
of initiating urate-lowering treatment.
Results: A total of 6133 people (4975 men and 1158 women) with two or more International
Classification of Disease-9 codes for gout were identified. As compared with men with gout, women were
older (mean age 70 (SD 13) v 58 (SD 14), p,0.001) and had comorbidities and received diuretics more
often (77% v 40%; p,0.001). Only 37% of new users of urate-lowering treatment had appropriate
surveillance of serum urate levels post-initiation of urate-lowering treatment. After controlling for age,
comorbidities, gout treatments, number of ULD dispensings and health plan, women were more likely
(odds ratio 1.36, 95% confidence interval 1.11 to 1.67) to receive the recommended serum urate level
testing.
Conclusions: Women with gout were older, had greater comorbidities and more often used diuretics and
received appropriate surveillance of serum urate levels, suggesting that the factors leading to gout as well
as monitoring of treatment are very different in women and men.
G
out is a common inflammatory arthropathy affecting
up to 5 million Americans, and the prevalence is
rising.1 Although gout has been studied for centuries,
only a handful of studies have examined sex differences in
gout epidemiology and treatment, and they included rela-
tively small numbers of women with gout.2–8 Most textbooks
describe gout as ‘‘predominantly a disease of men’’.9 Also,
much of the recent gout research has focused solely on men
and has not included women.4–6 However, among those
.60 years of age, the incidence of gout in women may be
equivalent to men.7
Over the past decade there have been several demographic
and treatment pattern changes that could potentially change
or magnify sex differences in gout epidemiology. These
changes include the ageing of the population,10 increased use
of thiazide diuretics as the preferred treatment for hyperten-
sion11 12 and increased prevalence of obesity13 14 and metabolic
syndrome15—all of which are risk factors for gout. Because
women live longer and have a higher prevalence of
hypertension after the age of 50 years than men,16 gout will
probably be of increasing concern in older women. Therefore,
further investigation into the potential sex differences in
the presentation, evaluation and treatment of gout are
warranted.
In our study, we examined differences between men and
women with gout in terms of risk factors (eg, age,
comorbidities and diuretic use), evaluation and treatment
patterns, and monitoring of serum urate levels after initiating
a urate-lowering drug (ULD) using the administrative
databases of seven health maintenance organisations
(HMOs). The limited literature on sex differences in the
clinical characteristics of adults with gout suggests that
women with gout tend to be older and have a higher
prevalence of comorbid disease.2 3 17 To the best of our
knowledge, no population-based studies have examined
how the risk factors of gout differ between women and
men and whether such differences influence the evaluation
and treatment of gout. We hypothesised that although the
drug and disease factors contributing to the development of
gout differ between women and men, the evaluation and
treatment of the condition would be similar.
METHODS
Setting
The study population included members from seven health
plans that are part of the HMO Research Network Center for
Education and Research on Therapeutics.18 The HMO
Research Network Center for Education and Research on
Therapeutics member organisations include staff, group,
network, independent practice association and mixed model
HMOs that provided healthcare for approximately 7 million
people in more than 1000 practice sites in the year 2000. We
chose a representative sample of roughly 200 000 members,
from each of the seven HMOs that participated, for inclusion
into the dataset. The sampling scheme and demographic
distribution of this population have been described else-
where.19 The dataset had computerised information on use of
Abbreviations: CPT, current procedural terminology; HMO, health
maintenance organisation; ICD, International Classification of Disease;
NSAIDs, non-steroidal anti-inflammatory drugs; ULD, urate-lowering
drug
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healthcare services, including membership information,
pharmacy dispensing data, and selected hospital and
ambulatory diagnoses and procedures, including laboratory
tests from 1 January 1999 to 31 December 2003. Institutional
review boards at each participating organisation approved
this study.
Study population and design
We identified members from the dataset who met the criteria
for enrolment into the ‘‘gout cohort’’. Criteria for inclusion in
the gout cohort were as follows: >19 years of age at the time
of the first gout diagnosis, two or more ambulatory visits at
least 30 days apart associated with an International
Classification of Disease-9 (ICD-9) code for a gout diagnosis
(ICD-9 codes 274.0, 274.1, 274.8, 274.9) and continuous
enrolment in the health plan with drug coverage during the
period 6 months before and 12 months after the first gout
diagnosis. Risk factors for gout (comorbidities and diuretic
use) and relevant laboratory testing and treatments were
identified during this period using the claims data. Age, as of
first gout diagnosis, and sex were ascertained from the
demographic data.
From the gout cohort, we identified new users of ULDs. A
new user was defined as a cohort member who received no
dispensing of a ULD (allopurinol, probenecid or sulfinpyr-
azone) during the 6 months before the gout diagnosis but
was subsequently dispensed a ULD. In this subset of gout
cohort patients, the same demographic and healthcare usage
information was gathered as described above during the
period 6 months before and 6 months after the first dispen-
sing of a ULD. Age at the time of the first dispensing of ULD
was used for the subsequent analyses.
We ascertained the presence of comorbidities from the
ICD-9 diagnosis codes associated with ambulatory care.
Comorbidities of interest included coronary heart disease,
diabetes mellitus, dyslipidaemia, hypertension, nephrolithia-
sis, peripheral arterial disease, renal insufficiency and renal
failure (table AI). Laboratory testing, including measurement
of serum urate levels, 24-h urine tests for uric acid secretion
and synovial fluid analyses, and joint or bursal diagnostic
aspirations and therapeutic injections were ascertained using
current procedural terminology (CPT) codes (table AII).
Aspirations and injections of joints and bursae have the
same CPT code; we were thus unable to differentiate between
them. Drug usage was identified by determining dispensings
using national drug codes for the following drug classes:
diuretics (thiazide, potassium-sparing, loop and others),
non-acetylated salicylates, both cyclooxygenase selective
and non-selective non-steroidal anti-inflammatory drugs
(NSAIDs), opioid analgesics, colchicine, uricosuric drugs,
allopurinol and glucocorticoids.
Analyses
Differences between men and women were evaluated using
t test or the Wilcoxon rank sum test for continuous variables
and x2 test or Fisher’s exact test for categorical variables.
Differences between women and men in the evaluation and
treatment of gout were assessed using multivariable logistic
regression, adjusting for age, total number of encounters
with a gout diagnosis, comorbidities, use of diuretics and
health plan. Odds ratio (OR) and 95% confidence intervals
(CI) were estimated.
We also compared new users of ULDs who received serum
urate monitoring within 6 months after initiating treatment
with those who did not, for demographic characteristics
(including age and sex), comorbidities, use of diuretics and
treatment practices. The 6-month time frame for serum urate
monitoring after initiation of a ULD was chosen based on the
gout quality-of-care indicators developed by Mikuls et al.20
Multivariable logistic regression was used to assess the
strength of association between sex and receipt of the
recommended surveillance of serum urate levels. We con-
trolled for number of encounters associated with a gout
diagnosis, as women may be more likely to receive laboratory
monitoring because they had more healthcare encounters for
gout than men. OR and 95% CI were estimated. Analyses
were conducted using SAS V.9.1.
RESULTS
Table 1 shows the characteristics of the study population. As
compared with men with gout, women with gout were older
and more often had hypertension, dyslipidaemia, coronary
heart disease, diabetes mellitus, peripheral arterial disease,
renal insufficiency and renal failure. Use of diuretics was
almost twofold greater in women than in men (thiazide
diuretics 55% v 30%; p,0.001 and any diuretic 77% v 40%;
p,0.001). The proportion of women with gout who had
serum urate levels tested during the period under study was
similar to that observed in men (table 2); however, after
controlling for age, number of encounters with a gout
diagnosis, comorbidities, use of diuretics and health plan,
women were more likely to have this test carried out.
Although 24-h urine tests for uric acid excretion were carried
out in a minority of patients, after multivariable adjustment
Table 1 Baseline characteristics of the study population*
Men Women
p Valuen % or SD n % or SD
Totals 4975 81% 1158 19%
Age (mean years) 58 14 70 12 ,0.001
Mean and median number of
encounters for gout 2.7, 2 3 2.9, 2 2 ,0.001
Gout-associated comorbidities
Hypertension 2833 57% 939 81% ,0.001
Dyslipidaemia 1894 38% 491 42% ,0.01
Coronary heart disease 943 19% 287 25% ,0.001
Peripheral arterial disease 202 4% 77 7% ,0.001
Diabetes mellitus 866 17% 350 30% ,0.001
Nephrolithiasis 153 3% 27 2% 0.18
Renal insufficiency 485 10% 204 18% ,0.001
Renal failure 308 6% 143 12% ,0.001
Drugs that can trigger or exacerbate
gout (receipt of >1 prescription)
Thiazide diuretics 1487 30% 636 55% ,0.001
All diuretics 2003 40% 897 77% ,0.001
* p Values represent comparisons between men and women for the variables listed.
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women were more likely to undergo this test. In adjusted
analyses, women were less likely to have synovial fluid cell
counts and synovial crystal analysis carried out, but no less
likely to receive diagnostic aspirations and therapeutic
injections.
Women were considerably more likely than men to receive
cyclooxygenase selective NSAIDs, non-acetylated salicylates,
narcotics and glucocorticoids (table 3). Interestingly, the
proportion of men and women who received allopurinol was
identical (56%). However, after accounting for confounding
variables, women were considerably less likely to receive this
drug.
Only 37% of new users of ULDs had serum urate levels
assessed within 6 months of starting a ULD. Even among
people who received six or more dispensings of a ULD in the
6-month period under study, only 45% received the recom-
mended surveillance. After controlling for age, comorbidities,
treatments for gout, number of visits associated with a
diagnosis of gout, number of ULD dispensings and health
plan, women were more likely (OR 1.36, 95% CI 1.11 to 1.67)
to receive surveillance of serum urate level (table 4).
DISCUSSION
Our study is the first to examine, from a population-based
perspective, sex differences in the population characteristics,
evaluation and treatment of gout. The differences between
women and men with gout are striking, as the women are
about a decade older, have more associated comorbidites and
are more likely to be taking diuretics. Over the past 20 years
there have been only four small studies specifically examin-
ing sex differences in clinical characteristics of gout, none of
which were population based.2 3 17 21 Lally et al2 in 1986
compared the clinical cases of 23 women with gout with 75
men with crystal-proven gout. As compared with the men,
the women were older, more likely to be receiving diuretics
and more often had renal insufficiency. Similarly, Puig et al3
in 1991 compared the clinical features of 37 women with
gout with 2002 men with gout. Here again, the women
developed gout at a later age, had more associated
comorbidities and received diuretics more often. Both
Meyers and Monteagudo17 and DeSouza et al21 examined
the medical records of women and men with gout and found
that women were more likely to have tophi or polyarticular
disease at presentation and upper extremity joint involve-
ment, suggesting potentially that in women the diagnosis of
gout may be delayed or the condition may be confused with
other forms of arthritis.
Our findings as well as those of others2 3 17 21 indicate that
the risk factors for gout in women are different from those in
men. For example, renal disease and receipt of diuretics, both
of which predispose to gout, were more common in women.
Current recommendations calling for the use of thiazide
diuretics as the preferred treatment for hypertension11 may
have important implications in terms of gout frequency,
particularly among older women. Hypertension, also an
independent risk factor for hyperuricaemia and gout, is more
common in women .50 years than in men of the same age.16
It was surprising that after adjustment for age, comorbid-
ities and use of diuretics, women were less likely to receive
allopurinol than men. In addition, it was interesting that
women in our study received glucocorticoids and narcotics
more often than men, possibly suggesting they had more
severe episodes, greater chronicity to their gout or intolerance
to other gout treatments; however, these drugs are not
specific for gout and could have been used for other
conditions. Further investigation into the management of
gout in women and men is needed to assess whether
treatment differences reflect appropriate care based on
differences in the clinical spectrum of gout.
As shown in our study, substantial proportions of people
who initiate treatment with ULDs do not receive surveillance
of serum urate levels after initiation of the drug.
Table 2 Differences between women and men with gout in diagnostic evaluation and surveillance during the period under
study
Test
Men Women Unadjusted Adjusted*
n % n % OR (95% CI) OR (95% CI)
Serum urate 3327 67 795 69 1.09 (0.95 to 1.25) 1.20 (1.02 to 1.40
24-h urine for uric acid
excretion
245 5 67 6 1.19 (0.90 to 1.57) 1.40 (1.04 to 1.90)
Synovial fluid cell count 226 5 34 3 0.64 (0.44 to 0.92) 0.56 (0.38 to 0.83)
Synovial crystal analysis 245 5 32 2 0.56 (0.38 to 0.80) 0.49 (0.34 to 0.72)
Diagnostic aspirations or
therapeutic joint or bursal
injections
771 15 217 19 1.26 (1.07 to 1.49) 1.10 (0.91 to 1.32)
*Adjusted for age, number of encounters with a gout diagnosis, gout-associated comorbidities (including hypertension, dyslipidaemia, coronary heart disease,
peripheral arterial disease, diabetes mellitus, nephrolithiasis, renal insufficiency and renal failure), use of diuretics and health plan.
Table 3 Treatment differences between women and men with gout
Treatments for gout (receipt of >1
prescription of the following)
Men Women Unadjusted Adjusted*
n % n % OR (95% CI) OR (95% CI)
Non-selective NSAID 3791 76 798 69 0.69 (0.60 to 0.80) 0.95 (0.80 to 1.11)
Selective NSAID 249 5 111 10 2.01 (1.59 to 2.54) 1.68 (1.29 to 2.18)
Non-acetylated salicylates 191 4 114 10 2.74 (2.15 to 3.48) 1.99 (1.54 to 2.58)
Narcotics 2336 47 698 60 1.71 (1.50 to 1.95) 1.44 (1.24 to 1.67)
Colchicine 2203 44 567 49 1.21 (1.06 to 1.37) 1.07 (0.93 to 1.24)
Uricosuric drug 201 4 57 5 1.23 (0.91 to 1.66) 1.16 (0.84 to 1.61)
Allopurinol 2792 56 647 56 0.99 (0.87 to 1.13) 0.78 (0.67 to 0.90)
Glucocorticoids 1631 33 488 42 1.49 (1.31 to 1.70) 1.30 (1.12 to 1.50)
NSAID, non-steroidal anti-inflammatory drug.
*Adjusted for age, number of encounters with a gout diagnosis, gout-associated comorbidities (including hypertension, dyslipidaemia, coronary heart disease,
peripheral arterial disease, diabetes mellitus, nephrolithiasis, renal insufficiency and renal failure), use of diuretics and health plan.
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Interestingly, women were more likely than men to receive
appropriate monitoring after controlling for age, comorbid-
ities, gout treatments, number of ULD dispensings and health
plan. Although beyond the scope of this study, potential
reasons for these differences could include greater vigilance
by doctors when treating women with gout owing to a
greater number of associated comorbidities and associated
drugs, more overall healthcare encounters by women result-
ing in greater opportunities for monitoring, or better
adherence by women with physician recommendations.
Because we cannot account for serum urate tests ordered
but not carried out, it is not possible to separate physician
non-adherence with ordering a recommended laboratory test
from patient non-adherence with obtaining the test.
An important strength of this study is that it includes a
large population of patients with two or more diagnoses of
gout at least 30 days apart, thus increasing the likelihood
that these people were truly considered to have gout by the
treating doctor. In addition, the patient sample is derived
from seven health plans across the USA and thus includes a
diversity of people. Limitations include lack of validation of
diagnostic and procedure claims data, although any bias that
occurred would be non-differential between women and
men. In addition, we cannot verify that the drugs examined
were prescribed for gout. We were unable to assess the
clinical implications of adherence and non-adherence with
the recommended surveillance of serum urate levels in terms
of provider response to serum urate levels, efficacy of urate-
lowering treatment and clinical outcomes. Lastly, our results
may not be generalisable to other health plans or other
systems of healthcare delivery. At a minimum, these results
are probably generalisable to at least 1 in 4 (24.6%) residents
in the USA who are enrolled in HMOs.22
In summary, this is the first population-based study
examining sex differences in gout epidemiology, evaluation
and treatment. The characteristics of women and men with
gout are strikingly different, suggesting different risk factors
for the condition. Of note, women were less likely to receive
allopurinol after controlling for confounders using multi-
variable logistic regression. Lastly, women with gout were
also more likely to receive the recommended surveillance of
serum urate levels within the first 6 months after ULD
initiation. This work suggests further investigation into
quality of care for gout to ensure that both women and
men with gout receive the recommended evaluation and
treatment.
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APPENDIX
International classification of diseases and current procedural
terminology codes for the various comorbidities analysed in
women with gout.
Table AII Ambulatory procedures codes of interest
Procedure CPT code
Diagnostic/therapeutic procedures
Aspiration or injections of bursa/joint 20600–20610
Laboratory tests
Arthritis panel 80072
Serum urate (uric acid) 84550
24-h urine for uric acid secretion 84560
Synovial fluid analysis
Cell count and differential 89050, 89051
Crystal analysis 89060
Gram stain and culture 87070
CPT, current procedural terminology.
Table A1 Ambulatory diagnostic codes of interest used
to identify relevant conditions
Diagnosis ICD-9 codes
Hypertension
Malignant 401.0x
Benign 401.1x
Unspecific 401.9x
Secondary 405.xx
Dyslipidaemia
Hyperlipidaemia 272.1-9x
Hypercholesterolaemia 272.0x
Coronary heart disease
Angina 413.xx
Bypass grafting 414.xx
Cardiovascular disease 429.2x
Acute myocardial infarction 410.xx
Old myocardial infarction 412.xx
Unstable angina 411.1x
Peripheral arterial disease
Peripheral vascular disease 443.9x
Diabetes mellitus
All forms of diabetes 250.xx
Nephrolithiasis
Calculi of kidney and ureter 592.xx
Uric acid stones 274.11
Renal insufficiency
Renal insufficiency 593.9x
Renal failure
Acute renal failure 584.xx
Chronic renal failure 585.xx
Renal failure unspecified 586.xx
ICD, International Classification of Diseases.
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